1 Saltiel AR & Pessin JE (2002) Insulin signalling pathways in time and space. Trends in Cell Biol 12, 65–71.
2 Pessin JE & Saltiel AR (2000) Signalling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106, 165–169.
3 Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106, 171–176.
4 Sathishseker D & Subramanian S (2005) Antioxidant properties of Momordica charantia (bitter gourd) seeds on streptozotocin induced diabetic rats. Asia Pac J Clin Nutr 14(2), 153–158.
5 Grover JK & Yadav SP (2004) Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol 93, 123–132.
6 Yibchok-Anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S & Hsu WH (2006) Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull 29(6), 1126–1131.
7 Miura T, Itoh Y, Iwamoto N, Kato M & Ishida T (2004) Suppressive activity of the fruit of Momordica charantia with exercise on blood glucose in type 2 diabetic mice. Biol Pharm Bull 27(2), 248–250.
8 Ali L, Khan AK, Mamun MI, Mosihuzzaman M, Nahar N, Nur-e-Alam M & Rokeya B (1993) Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of Momordica charantia on normal and diabetic model rats. Planta Med 59(5), 408–412.
9 Ahmed I, Lakhani MS, Gillett M, John A & Raza H (2001) Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 51(3), 155–161.
10 Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR & Suzuki I (2001) Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol 47(5), 340–344.
11 Roffey BW, Atwal AS, Johns T & Kubow S (2007) Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. J Ethnopharmacol 30, 77–84.
12 Storlien LH, James DE, Burleigh KM, Chisholm DJ & Kraegen EW (1986) Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J physiol 251, E576–E583.
13 Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ & Bignell AHC (1981) Improvement in glucose tolerance due to Momordica charantia (karela). Brit Med J 282, 1823–1824.
14 Minsheng Y, Nicky K, Jongsoon L, Lone H, Zhi-Wei Li, Micheal K & Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 293, 1673–1677.
15 Youngren JF, John P & Barnard RJ (2001) Impaired insulin- receptor autophosphorylation is an early defect in fat-fed, insulin resistant rats. Am J Physiol 91, 2240–2247.
16 Saad MJA, Araki E, Miralpeix M, Rothenberg PL, White MF & Kohn CR (1992) Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 90, 1839–1849.
17 Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantity of protein utilizing the principle of protein dye binding. Anal Biochem 72, 248–254.
18 Laemmli UK (1970) Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature 227, 680–685.
19 Hansen PA, Han DH, Marshall BA, Nolte LA, Chen MM, Mueckler M & Holloszy JO (1998) A high fat diet impairs insulin stimulation of glucose transport in muscle. J Biol chem 273, 26157–26163.
20 Barnard RJ, Berger JJ, Ong JM & Kern PA (1998) Adipocyte and muscle changes in response to diet leading to obesity. Diabetes 33, 213–228.
21 Barnard RJ, Roberts CK, Varon SM & Berger JJ (1998) Diet induced insulin resistance precedes other aspects of metabolic syndrome. J Appl physiol 84, 1311–1315.
22 Oakes ND, Cooney GJ, Camilleri S, Chisholm DJ & Kraegen EW (1997) Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 46, 1768–1774.
23 White MF (1998) The IRS-signaling system: a network of docking protein that mediate insulin and cytokine action. Recent Prog Horm Res 53, 119–138.
24 Tamemoto H, Kadowaki T, Tobe K, et al. (1994) Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372, 182–186.
25 Yamauchi T, Tobe K, Tamemoto H, et al. (1996) Insulin signalling and insulin actions in the muscles and livers of insulin resistant, insulin receptor substrate 1- deficient mice. Mol Cell Biol 16, 3074–3084.
26 Tanti JF, Gremeaux T, Van Obberghen E, et al. (1994) Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin signalling. J Biol Chem 269, 6051–6057.
27 De Fea K & Roth RA (1997) Modulation of insulin receptor substrate -1 tyrosine phosphorylation and function by mitogen activated protein kinase. J Biol Chem 272, 31400–31406.
28 Grover JK & Yadav SP (2004) Pharmacological actions and uses of Momordica charantia: a review. J Ethanopharmacol 93(1), 123–132.
29 Xiang L, Huang X, Chen L, Rao P & Ke L (2007) The reparative effects of Momordica Charantia Linn. extract on HIT-T15 pancreatic beta-cells. Asia Pac J Clin Nutr 16(1), 249–252.
30 Chuang CY, Hsu C, Chao CY, Wein YS, Kuo YH & Huang CJ (2006) Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPAR alpha in bitter gourd (Momordica charantia L.). J Biomed Sci 13(6), 763–772.
31 Chao CY & Huang CJ (2003) Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. J Biomed Sci 10(2), 782–791.
32 Beatrice D & Walter W (1999) Peroxisome proliferator – activated receptors: nuclear control of metabolism. Endocrine Reviews 20(5), 649–688.
33 Kersten S, Desvergne B & Wahli W (2000) Roles of PPARs in health and disease. Diabetes 405, 421–424.
34 Spiegelmen BM (1997) PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507–514.
35 Ji Ming Ye, Patric JD, Miguel A, et al. (2001) Peroxisome proliferator-activated receptor (PPAR) – α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats. Comparison with PPAR-γ activation. Diabetes 50, 411–417.
36 Forman BM, Chen J & Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 94, 4312–4317.
37 Guerre-Millo M, Gervois P, Raspe E, et al. (2000) Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275, 16638–16642.
38 Werner DE, Lee J, Hansen L, Yuan M & Shoelson SE (2004) Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J Biol Chem 279, 35298–35305.
39 Kim JK, Kim YJ, Fillmore JJ, et al. (2001) Prevention of fat induced insulin resistance by salicylate. J clin Invest 108, 437–448.
40 Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H & Zick Y (1997) A molecular basis for insulin resistance: elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to under go insulin stimulated tyrosine phosphorylation. J Biol Chem 272, 29911–29918.
41 Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M & Shoelson SE (2001) Reversal of obesity and diet induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 293, 1673–1677.
42 Sykiotis GP & Papavassiliou AG (2001) Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. Molecular Endocrinology 15, 1864–1869.